nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—HTR2A—narcolepsy	0.755	1	CbGaD
Duloxetine—SLC6A2—locus ceruleus—narcolepsy	0.0158	0.145	CbGeAlD
Duloxetine—HTR2A—enteric nervous system—narcolepsy	0.0143	0.132	CbGeAlD
Duloxetine—HTR2A—locus ceruleus—narcolepsy	0.00947	0.0869	CbGeAlD
Duloxetine—SLC6A2—autonomic nervous system—narcolepsy	0.00837	0.0768	CbGeAlD
Duloxetine—NPY1R—forebrain—narcolepsy	0.00575	0.0527	CbGeAlD
Duloxetine—HTR2A—pons—narcolepsy	0.00546	0.0501	CbGeAlD
Duloxetine—HTR2A—autonomic nervous system—narcolepsy	0.00503	0.0462	CbGeAlD
Duloxetine—HTR6—forebrain—narcolepsy	0.00404	0.0371	CbGeAlD
Duloxetine—SLC6A3—brainstem—narcolepsy	0.00251	0.023	CbGeAlD
Duloxetine—HTR2C—brainstem—narcolepsy	0.00242	0.0222	CbGeAlD
Duloxetine—SLC6A3—forebrain—narcolepsy	0.00242	0.0222	CbGeAlD
Duloxetine—NPY1R—brain—narcolepsy	0.00238	0.0219	CbGeAlD
Duloxetine—HTR2C—forebrain—narcolepsy	0.00234	0.0215	CbGeAlD
Duloxetine—SLC6A4—brainstem—narcolepsy	0.0023	0.0211	CbGeAlD
Duloxetine—SLC6A4—forebrain—narcolepsy	0.00222	0.0203	CbGeAlD
Duloxetine—SLC6A2—brainstem—narcolepsy	0.00202	0.0185	CbGeAlD
Duloxetine—SLC6A2—forebrain—narcolepsy	0.00195	0.0179	CbGeAlD
Duloxetine—HTR2C—medulla oblongata—narcolepsy	0.00169	0.0155	CbGeAlD
Duloxetine—HTR6—brain—narcolepsy	0.00168	0.0154	CbGeAlD
Duloxetine—SLC6A3—midbrain—narcolepsy	0.0016	0.0147	CbGeAlD
Duloxetine—HTR2C—midbrain—narcolepsy	0.00154	0.0142	CbGeAlD
Duloxetine—SLC6A4—midbrain—narcolepsy	0.00146	0.0134	CbGeAlD
Duloxetine—SLC6A2—medulla oblongata—narcolepsy	0.00141	0.0129	CbGeAlD
Duloxetine—HTR2A—brainstem—narcolepsy	0.00121	0.0111	CbGeAlD
Duloxetine—HTR2A—forebrain—narcolepsy	0.00117	0.0108	CbGeAlD
Duloxetine—CYP2D6—brainstem—narcolepsy	0.00111	0.0102	CbGeAlD
Duloxetine—CYP2D6—forebrain—narcolepsy	0.00107	0.0098	CbGeAlD
Duloxetine—SLC6A3—brain—narcolepsy	0.001	0.00921	CbGeAlD
Duloxetine—HTR2C—brain—narcolepsy	0.00097	0.0089	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.000949	0.00706	CbGpPWpGaD
Duloxetine—SLC6A4—brain—narcolepsy	0.000919	0.00844	CbGeAlD
Duloxetine—HTR6—Amine ligand-binding receptors—HTR2A—narcolepsy	0.000887	0.0066	CbGpPWpGaD
Duloxetine—HTR2A—medulla oblongata—narcolepsy	0.000847	0.00777	CbGeAlD
Duloxetine—NPY1R—GPCR ligand binding—TRH—narcolepsy	0.000824	0.00613	CbGpPWpGaD
Duloxetine—SLC6A2—brain—narcolepsy	0.000809	0.00743	CbGeAlD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.000786	0.00585	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.000786	0.00585	CbGpPWpGaD
Duloxetine—Fluoxetine—HTR2A—narcolepsy	0.000784	0.609	CrCbGaD
Duloxetine—HTR2C—Monoamine GPCRs—HTR2A—narcolepsy	0.000777	0.00578	CbGpPWpGaD
Duloxetine—HTR2A—midbrain—narcolepsy	0.000774	0.00711	CbGeAlD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.000749	0.00557	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.000749	0.00557	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HCRTR2—narcolepsy	0.000748	0.00557	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HCRTR1—narcolepsy	0.000748	0.00557	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.000723	0.00538	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—P2RY11—narcolepsy	0.000723	0.00538	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—HRH3—narcolepsy	0.000723	0.00538	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HCRTR2—narcolepsy	0.000713	0.00531	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HCRTR1—narcolepsy	0.000713	0.00531	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—P2RY11—narcolepsy	0.000689	0.00513	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HCRTR1—narcolepsy	0.000679	0.00506	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HCRTR2—narcolepsy	0.000679	0.00506	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—P2RY11—narcolepsy	0.000656	0.00488	CbGpPWpGaD
Duloxetine—HTR2C—Amine ligand-binding receptors—HTR2A—narcolepsy	0.000653	0.00486	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.000641	0.00477	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.000641	0.00477	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR2—narcolepsy	0.000638	0.00475	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR1—narcolepsy	0.000638	0.00475	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.000619	0.00461	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—HCRTR1—narcolepsy	0.000619	0.00461	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—HCRTR2—narcolepsy	0.000619	0.00461	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—P2RY11—narcolepsy	0.000616	0.00458	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HCRT—narcolepsy	0.000614	0.00457	CbGpPWpGaD
Duloxetine—HTR6—G alpha (s) signalling events—NPS—narcolepsy	0.000608	0.00453	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—TAC1—narcolepsy	0.000599	0.00446	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—NPS—narcolepsy	0.000599	0.00446	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—P2RY11—narcolepsy	0.000598	0.00445	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HCRT—narcolepsy	0.000586	0.00436	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HCRT—narcolepsy	0.000558	0.00415	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR1—narcolepsy	0.000554	0.00412	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HCRTR2—narcolepsy	0.000554	0.00412	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.000552	0.00411	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.000551	0.0041	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.000551	0.0041	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—PENK—narcolepsy	0.000548	0.00408	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.000538	0.004	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—P2RY11—narcolepsy	0.000535	0.00398	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.000532	0.00396	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.000527	0.00392	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HCRT—narcolepsy	0.000524	0.0039	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—HCRT—narcolepsy	0.000509	0.00378	CbGpPWpGaD
Duloxetine—Atomoxetine—HTR2A—narcolepsy	0.000504	0.391	CrCbGaD
Duloxetine—NPY1R—Signaling by GPCR—PENK—narcolepsy	0.000497	0.0037	CbGpPWpGaD
Duloxetine—SLC6A4—Monoamine Transport—TNF—narcolepsy	0.000494	0.00368	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HCRTR2—narcolepsy	0.000488	0.00363	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HCRTR1—narcolepsy	0.000488	0.00363	CbGpPWpGaD
Duloxetine—HTR2A—brain—narcolepsy	0.000487	0.00446	CbGeAlD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HCRTR2—narcolepsy	0.000479	0.00356	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HCRTR1—narcolepsy	0.000479	0.00356	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.000473	0.00352	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.000472	0.00351	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.000472	0.00351	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—P2RY11—narcolepsy	0.000472	0.00351	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.000469	0.00349	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TRH—narcolepsy	0.000466	0.00347	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—P2RY11—narcolepsy	0.000462	0.00344	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.000456	0.00339	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HCRT—narcolepsy	0.000455	0.00338	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—TRH—narcolepsy	0.000444	0.0033	CbGpPWpGaD
Duloxetine—CYP2D6—brain—narcolepsy	0.000443	0.00407	CbGeAlD
Duloxetine—SLC6A4—Circadian rythm related genes—NPS—narcolepsy	0.000439	0.00327	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—TNF—narcolepsy	0.000425	0.00316	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TRH—narcolepsy	0.000423	0.00315	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HCRTR1—narcolepsy	0.00041	0.00305	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HCRTR2—narcolepsy	0.00041	0.00305	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.000409	0.00304	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HRH3—narcolepsy	0.000408	0.00304	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HCRTR2—narcolepsy	0.000401	0.00299	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HCRTR1—narcolepsy	0.000401	0.00299	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HCRT—narcolepsy	0.000401	0.00298	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.000399	0.00297	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—narcolepsy	0.000397	0.00295	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—P2RY11—narcolepsy	0.000396	0.00295	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.000388	0.00289	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—P2RY11—narcolepsy	0.000388	0.00288	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—TRH—narcolepsy	0.000385	0.00287	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TNF—narcolepsy	0.000376	0.0028	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HRH3—narcolepsy	0.000371	0.00276	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—HTR2A—narcolepsy	0.00036	0.00268	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HCRTR2—narcolepsy	0.00036	0.00268	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HCRTR1—narcolepsy	0.00036	0.00268	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—PENK—narcolepsy	0.000357	0.00266	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.00035	0.0026	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—P2RY11—narcolepsy	0.000347	0.00258	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.000346	0.00257	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—narcolepsy	0.000345	0.00257	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—NPS—narcolepsy	0.000338	0.00252	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—TAC1—narcolepsy	0.000338	0.00252	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HCRT—narcolepsy	0.000337	0.00251	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HCRT—narcolepsy	0.00033	0.00245	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TAC1—narcolepsy	0.000324	0.00241	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—narcolepsy	0.000324	0.00241	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—TAC1—narcolepsy	0.000323	0.0024	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—NPS—narcolepsy	0.000323	0.0024	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HCRTR1—narcolepsy	0.000312	0.00232	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HCRTR2—narcolepsy	0.000312	0.00232	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—TAC1—narcolepsy	0.000307	0.00229	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—NPS—narcolepsy	0.000307	0.00229	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TRH—narcolepsy	0.000304	0.00226	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—P2RY11—narcolepsy	0.000302	0.00224	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.000301	0.00224	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—PENK—narcolepsy	0.0003	0.00223	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HCRT—narcolepsy	0.000295	0.0022	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.000294	0.00219	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PENK—narcolepsy	0.000294	0.00219	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.00029	0.00216	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.00029	0.00216	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—narcolepsy	0.000288	0.00215	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—narcolepsy	0.000288	0.00215	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—NPS—narcolepsy	0.00028	0.00208	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—TAC1—narcolepsy	0.00028	0.00208	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HCRTR1—narcolepsy	0.000276	0.00205	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HCRTR2—narcolepsy	0.000276	0.00205	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—P2RY11—narcolepsy	0.000267	0.00198	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HRH3—narcolepsy	0.000267	0.00198	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—PENK—narcolepsy	0.000263	0.00196	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—HRH3—narcolepsy	0.000261	0.00194	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.000258	0.00192	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HCRT—narcolepsy	0.000256	0.00191	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TRH—narcolepsy	0.000255	0.0019	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HCRTR2—narcolepsy	0.000251	0.00187	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HCRTR1—narcolepsy	0.000251	0.00187	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NPS—narcolepsy	0.00025	0.00186	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TAC1—narcolepsy	0.00025	0.00186	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TRH—narcolepsy	0.00025	0.00186	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—P2RY11—narcolepsy	0.000242	0.0018	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—PENK—narcolepsy	0.000229	0.0017	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HCRT—narcolepsy	0.000227	0.00169	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—TRH—narcolepsy	0.000224	0.00167	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—HRH3—narcolepsy	0.000224	0.00167	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TAC1—narcolepsy	0.000221	0.00164	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—NPS—narcolepsy	0.000221	0.00164	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HRH3—narcolepsy	0.000219	0.00163	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.000214	0.00159	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.000214	0.00159	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HCRT—narcolepsy	0.000206	0.00153	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.000204	0.00152	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—HTR2A—narcolepsy	0.000204	0.00151	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HCRTR1—narcolepsy	0.000203	0.00151	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HCRTR2—narcolepsy	0.000203	0.00151	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PENK—narcolepsy	0.000202	0.0015	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—P2RY11—narcolepsy	0.000196	0.00146	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HRH3—narcolepsy	0.000196	0.00146	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TRH—narcolepsy	0.000194	0.00145	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—HTR2A—narcolepsy	0.000194	0.00144	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAC1—narcolepsy	0.000185	0.00138	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—NPS—narcolepsy	0.000185	0.00138	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—HTR2A—narcolepsy	0.000185	0.00138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HCRTR2—narcolepsy	0.000185	0.00137	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HCRTR1—narcolepsy	0.000185	0.00137	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PENK—narcolepsy	0.000183	0.00137	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TAC1—narcolepsy	0.000182	0.00135	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NPS—narcolepsy	0.000182	0.00135	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—P2RY11—narcolepsy	0.000178	0.00133	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HCRTR1—narcolepsy	0.000177	0.00131	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HCRTR2—narcolepsy	0.000177	0.00131	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.000174	0.0013	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—narcolepsy	0.000174	0.00129	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TRH—narcolepsy	0.000172	0.00128	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—P2RY11—narcolepsy	0.00017	0.00127	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—HRH3—narcolepsy	0.00017	0.00127	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HCRT—narcolepsy	0.000167	0.00124	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—TAC1—narcolepsy	0.000163	0.00121	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—NPS—narcolepsy	0.000163	0.00121	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HCRTR1—narcolepsy	0.00016	0.00119	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HCRTR2—narcolepsy	0.00016	0.00119	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TRH—narcolepsy	0.000156	0.00116	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—P2RY11—narcolepsy	0.000155	0.00115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HCRT—narcolepsy	0.000152	0.00113	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HRH3—narcolepsy	0.000151	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—HTR2A—narcolepsy	0.00015	0.00112	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PENK—narcolepsy	0.000149	0.00111	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HCRTR1—narcolepsy	0.000148	0.0011	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HCRTR2—narcolepsy	0.000148	0.0011	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CHKB—narcolepsy	0.000145	0.00108	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HCRT—narcolepsy	0.000145	0.00108	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—P2RY11—narcolepsy	0.000143	0.00106	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—NPS—narcolepsy	0.000141	0.00105	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—TAC1—narcolepsy	0.000141	0.00105	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—narcolepsy	0.000139	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRH3—narcolepsy	0.000137	0.00102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PENK—narcolepsy	0.000135	0.00101	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—HTR2A—narcolepsy	0.000133	0.000989	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HCRT—narcolepsy	0.000132	0.000979	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PENK—narcolepsy	0.000129	0.000961	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—narcolepsy	0.000128	0.000956	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TRH—narcolepsy	0.000127	0.000941	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—NPS—narcolepsy	0.000125	0.000929	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TAC1—narcolepsy	0.000125	0.000929	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HCRT—narcolepsy	0.000122	0.000905	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PENK—narcolepsy	0.000117	0.000873	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TRH—narcolepsy	0.000115	0.000855	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NPS—narcolepsy	0.000113	0.000843	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TAC1—narcolepsy	0.000113	0.000843	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—narcolepsy	0.000112	0.000831	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—narcolepsy	0.000112	0.000831	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HRH3—narcolepsy	0.000111	0.000825	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TRH—narcolepsy	0.00011	0.000817	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—HTR2A—narcolepsy	0.000109	0.000813	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HCRTR1—narcolepsy	0.000109	0.000811	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HCRTR2—narcolepsy	0.000109	0.000811	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PENK—narcolepsy	0.000108	0.000806	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—P2RY11—narcolepsy	0.000105	0.000784	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRH3—narcolepsy	0.000101	0.00075	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TRH—narcolepsy	9.98e-05	0.000742	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—narcolepsy	9.86e-05	0.000734	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—HTR2A—narcolepsy	9.78e-05	0.000728	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—HRH3—narcolepsy	9.63e-05	0.000717	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HCRTR2—narcolepsy	9.47e-05	0.000705	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HCRTR1—narcolepsy	9.47e-05	0.000705	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TRH—narcolepsy	9.22e-05	0.000686	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TAC1—narcolepsy	9.19e-05	0.000684	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—NPS—narcolepsy	9.19e-05	0.000684	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—P2RY11—narcolepsy	9.14e-05	0.000681	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HCRT—narcolepsy	8.95e-05	0.000666	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRH3—narcolepsy	8.75e-05	0.000651	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—narcolepsy	8.38e-05	0.000623	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NPS—narcolepsy	8.35e-05	0.000621	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TAC1—narcolepsy	8.35e-05	0.000621	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRH3—narcolepsy	8.08e-05	0.000601	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—NPS—narcolepsy	7.98e-05	0.000594	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TAC1—narcolepsy	7.98e-05	0.000594	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PENK—narcolepsy	7.98e-05	0.000594	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HCRT—narcolepsy	7.78e-05	0.000579	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CHKB—narcolepsy	7.63e-05	0.000567	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—HTR2A—narcolepsy	7.51e-05	0.000559	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NPS—narcolepsy	7.25e-05	0.000539	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TAC1—narcolepsy	7.25e-05	0.000539	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PENK—narcolepsy	6.93e-05	0.000516	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HTR2A—narcolepsy	6.82e-05	0.000507	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TRH—narcolepsy	6.79e-05	0.000505	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TAC1—narcolepsy	6.7e-05	0.000498	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NPS—narcolepsy	6.7e-05	0.000498	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CHKB—narcolepsy	6.46e-05	0.000481	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRH3—narcolepsy	5.95e-05	0.000443	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TRH—narcolepsy	5.89e-05	0.000439	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—HTR2A—narcolepsy	5.53e-05	0.000411	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CPT1B—narcolepsy	5.18e-05	0.000386	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRH3—narcolepsy	5.17e-05	0.000385	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HTR2A—narcolepsy	5.02e-05	0.000374	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TAC1—narcolepsy	4.93e-05	0.000367	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NPS—narcolepsy	4.93e-05	0.000367	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CPT1B—narcolepsy	4.39e-05	0.000327	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TAC1—narcolepsy	4.28e-05	0.000319	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NPS—narcolepsy	4.28e-05	0.000319	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HTR2A—narcolepsy	4.03e-05	0.0003	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HTR2A—narcolepsy	2.97e-05	0.000221	CbGpPWpGaD
